CALGENT BIOTECHNOLOGY CO., LTD.
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
Calgent’s drug pipeline includes several novel therapeutic candidates. Their lead asset, CAL056 (Hectinib), is an oral first‑in‑class HECT-domain E3 ubiquitin ligase inhibitor for the treatment of multiple myeloma, which has received Orphan Drug Designati
Founded Year
2019
Unified Business No.
85127916
Status
Active
Number of Employees
0
Total Paid-in
Capital
78,333,334 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Calgent Biotechnology Co., Ltd. is a Taiwan-based biotech startup headquartered in Taipei. Founded in 2019, the company focuses on developing first-in-class small molecule therapeutics to address unmet medical needs. Calgent brings together expertise in t
